

People

Appointments

New president at Accelrys

Pharmacopeia (<http://www.pharmacopeia.com>) have announced the appointment of Mark J. Emkjer as President of Accelrys (<http://www.accelrys.com>), the company's wholly owned software subsidiary.

Joseph A. Mollica, Chairman, President and CEO of Pharmacopeia, said: 'It gives me great pleasure to welcome Mark to the Pharmacopeia team as President of Accelrys. Mark's extensive leadership experience in software management and the success he has demonstrated in generating growth, improving operating profits and creating shareholder value will be of tremendous benefit to our company.'

Emkjer brings more than 20 years of management experience to Accelrys, most recently as President and Chief Operating Officer of Sunquest Information Systems.

Accelrys is a leading provider of software for computation, simulation and the management and mining of scientific data for product design, drug discovery and development.

Discovery Partners International appoints Douglas A. Livingstone

Douglas A. Livingstone has been appointed as Senior Vice President and General Manager of the Discovery Chemistry Division at Discovery Partners International (<http://www.discoverypartners.com>).

Taylor Crouch, President and Chief Operating Officer, commented: 'Doug brings us 20 years of leadership expertise in the areas of pharmaceutical and biotech R&D, and I am delighted he has joined our management team as the leader of our Discovery Chemistry division.'

Livingstone said, 'Discovery Partners has an outstanding reputation as a pioneer in early discovery collaboration, and it is an honour to team up with its outstanding group of scientists, drug developers and management.'

Livingstone has held significant research management positions in the industry, including Upjohn, Burroughs Wellcome (now GlaxoSmithKline), La Jolla

Pharmaceutical, Axys Pharmaceuticals and the Genomics Institute of the Novartis Research Foundation. Most recently he served as VP, Chemistry and New Technologies at Structural Genomix.

Celera appoints new Head of Development

Celera Genomics (<http://www.celera.com>) have announced the appointment of James P. Yee as Head of Development, effective from 6 January 2003.

Yee will be responsible for building the development organization at Celera South San Francisco and for leading therapeutic development and clinical trial processes at Celera.

He will report to Robert Booth, Senior Vice President of R&D at Celera, who said: 'Jim possesses extensive drug development experience in disease areas of interest to Celera. Throughout his career, he has demonstrated an ability to build effective development teams and to integrate preclinical and clinical development activities with basic science and business planning.'

Yee has over 20 years experience in pharmaceutical R&D leadership, his most recent position being VP, Clinical and Preclinical Research for the Inflammatory and Viral Diseases Unit at Roche Bioscience.

All change in senior management at Cytogen

Cytogen (<http://www.cytogen.com>) Board of Directors has accepted the resignation of H. Joseph Reiser as President and CEO; he will continue to serve as a director of the company. James A. Grigsby, Chairman of the Board of Directors, said: 'Joe Reiser has played a critical role in building Cytogen into a product-driven, oncology-focussed organization over the past five years.'

The Board has elected Michael D. Becker as President and CEO and also to the company's Board. Prior to this appointment, Becker served as VP, Business Development and Industry Relations. 'We believe Michael is well suited to be Cytogen's new CEO and maintain the company's sound corporate governance practices.'

In connection with these changes, the Board has accepted the resignation of Lawrence R. Hoffman, VP and Chief Financial Officer, and has announced the promotion of Thu Dang as VP, Finance from her current position as Director of Finance.

Replidyne appoints VP, Corporate Development and Scientific Directors

Replidyne (<http://www.replidyne.com>), a Colorado-based drug discovery company that focusses on identifying and developing drugs to treat serious infectious diseases, has announced the appointment of a Vice President, Corporate Development and three scientific directors to its management team.

Donald Morrissey recently joined the company as VP, Corporate Development. Prior to this, he held the position of VP, Legals Affairs and Business Development at Caliper Technologies. Kenneth Collins, President and CEO of Replidyne, said: 'We intend to aggressively in-license additional antibacterial programs to complement our core technology. We believe that Don's extensive experience in negotiating and structuring biotechnology strategic alliances will be invaluable to that process.'

Burton Goodman has joined Replidyne as Director, Informatics and Automation. He has 15 years of experience in medicinal chemistry, combinatorial chemistry, automation and IT.

The appointment of Director, Lead Discovery goes to Garry Dallmann, who spent three years in the Antimicrobial and Lead Discovery departments at Tularik and three years as a Senior Scientist in the antifungal group at Ribogene.

Most recently, Ian Critchley joined the company as Director of Microbiology, bringing more than 15 years of experience in antibacterial drug discovery and development.

'With the addition of this strong group of scientific directors, Replidyne is poised to significantly advance its efforts in discovering and developing novel antibacterial drugs with unique mechanisms of action', said Nebojsa Janjic, VP, R&D and founder of Replidyne.

People was written by
Joanne Clough